A5084354003- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
- Salivary Gland Tumors Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Retinoids in leukemia and cellular processes
- Polyomavirus and related diseases
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Bone and Joint Diseases
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
Institut Català d'Oncologia
2016-2025
Hospital Universitari Germans Trias i Pujol
2016-2025
Universitat Autònoma de Barcelona
2016-2025
Josep Carreras Leukaemia Research Institute
2016-2025
Fundación Josep Carreras Contra la Leucemia
2015-2024
Vilnius University
2023
Institut Català d'Ornitologia
2023
Instituto de Salud Carlos III
2022
Institut d'Investigació Biomédica de Bellvitge
2022
John Wiley & Sons (United States)
2020
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials showed efficacy manageable toxic effects.In this multi-institutional phase 3 trial, we randomly assigned adults heavily pretreated ALL, 2:1 ratio, receive either blinatumomab standard-of-care...
Complete response (CR) is considered an important goal in most hematologic malignancies. However, multiple myeloma (MM), there no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) overall (OS) of these responses pre- post-transplantation newly diagnosed patients MM.We analyzed 632 from prospective Grupo Español de Mieloma 2000...
Background About one half of adults with acute lymphoblastic leukemia are not cured the disease and ultimately die. The objective this study was to explore factors influencing outcome adult patients relapsed leukemia.Design Methods We analyzed characteristics, prognostic for survival after first relapse in a series 263 (excluding those mature B-cell leukemia) prospectively enrolled four consecutive risk-adapted PETHEMA trials.Results median overall 4.5 months (95% CI, 4–5 months) 5-year 10%...
<b>Objective</b> To investigate the effect of an additional review based on reporting guidelines such as STROBE and CONSORT quality manuscripts. <b>Design</b> Masked randomised trial. <b>Population</b> Original research manuscripts submitted to <i>Medicina Clínica</i> journal from May 2008 April 2009 considered suitable for publication. <b>Intervention</b> Control group: conventional peer reviews alone. Intervention plus looking missing items guidelines. <b>Outcomes</b> Manuscript quality,...
Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent adult patients (age 15 to 60 years) high-risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome chemotherapy or allogeneic hematopoietic stem-cell transplantation...
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients Ph-negative B-precursor diagnosed between 1990-2013 was conducted using data reflecting the standard care from 11 study groups large centers in Europe United States. Outcomes included complete remission, overall survival, realization stem cell...
Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.This was a Spanish transplant group cell therapy (GETH) multicenter retrospective observational study, which included large cohort blood cancer laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020.We 367 pediatric adult malignancies, including recipients autologous (ASCT) (n = 58) or allogeneic stem transplantation (allo-SCT) 65) 41...
Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits and all single-mutation variants, including T315I. Objective To compare frontline ponatinib vs imatinib in adults with Ph+ ALL. Design, Setting, Participants Global registrational, phase 3, open-label trial aged 18 years older From January 2019 May...
Abstract Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need guidance regarding management of (ALL) diagnosis to aftercare. The has previously summarized their recommendations diagnostic approaches, prognostic factors, and assessment ALL. current recommendation summarizes clinical management. It covers treatment including use new immunotherapies, application minimal residual disease decisions, specific subgroups,...
Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups knowledge on disease biology therapeutic options is increasing exponentially. The Group for Adult ALL therefore summarized current state art provided comprehensive recommendations diagnostic approaches, biologic characterization, prognostic factors, risk stratification as well definitions endpoints outcomes....
The goal of this study was to analyze the presenting features, natural history, and prognostic factors in 59 patients with well characterized mantle cell lymphoma (MCL).Cases were classified as nodular or diffuse typical blastic variants. Age, performance status (PS), histologic variants, mitotic index (MI), hematologic parameters, tumor extension data, International Prognostic Index (IPI) recorded evaluated for prognosis.The median age 63 years (range, 39-83 years), male female ratio 3:1....
Retrospective studies have shown that adolescents and young adults with acute lymphoblastic leukemia (ALL) treated pediatric protocols better outcomes than similarly aged patients adult protocols, but prospective comparing using schedules are scarce. The ALL-96 protocol was addressed to compare the toxicity results of a pediatric-based in (age 15-18 years) 19-30 standard-risk (SR) ALL.Adolescents (n = 35) 46) received standard five-drug/5-week induction course followed by two cycles early...
Reduced-intensity conditioning (RIC) for allogeneic stem-cell transplantation (allo-SCT) reduces nonrelapse mortality (NRM). This reduction makes it possible patients who are ineligible high-dose myeloablative allo-SCT to benefit from graft-versus-leukemia reaction. In this multicenter, prospective study of with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), we investigated the efficacy RIC a human leukocyte antigen-identical sibling by using regimen that uses...
To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM).We have prospectively analyzed antigenic markers, assessed by multiparametric flow cytometry, a series 685 newly diagnosed MM that were uniformly treated according to GEM 2000 protocol.Our results show expression both CD19 and CD28 as well absence CD117 associated significantly shorter progression free-survival (PFS) overall survival (OS). Interestingly, correlated t(14;16) del(17p), while...
Background Although Hodgkin’s lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line even high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic transplantation in this setting.Design Methods In phase II study 92 relapsed an HLA-identical sibling, matched unrelated donor one antigen mismatched, were treated salvage followed by reduced intensity Fourteen...